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1. Introduction
Acute leukemias are highly malignant neoplasms and are responsible for a large number of
haematopoietic cancer-related deaths (Jemal et al 2006). Although the survival rates have
improved remarkably in the younger age group, the prognosis in older patients is still poor
(Redaelli et al 2003).
The  clinical  presentation  of  acute  leukemia  results  from infiltration  of  bone  marrow or
extramedullary sites by blasts. As a result, initial symptoms may be due to the presence
of anemia, neutropenia, or thrombocytopenia. Patients generally present with nonspecific
complaints  including weakness,  lethargy,  fatigue,  dyspnea,  fever,  weight  loss,  or  bleed‐
ing. Blasts may also infiltrate organs or lymph nodes, resulting in hepatosplenomegaly or
adenopathy.  Bone  marrow  infiltration  with  blasts  can  result  in  bone  pain.  Mucosal
bleeding,  petechiae,  ecchymosis,  and  fundal  hemorrhages  may  occur  as  a  result  of
thrombocytopenia.
Patients with acute promyelocytic leukemia (APL) characteristically present with coagulop‐
athy and signs of disseminated intravascular coagulation (DIC). It should be noted, however,
that rapid cell turnover can result in DIC in any form of acute leukemia.
In acute monocytic leukemia the common findings are weakness, bleeding and a diffuse
erythematous skin rash. There is a high frequency of extramedulary infiltration of the lungs,
colon, meninges, lymphnodes, bladder and larynx and gingival hyperplasia.
The clinical onset of acute lymphoblastic leukemia (ALL) is most often acute, although a small
percentage of cases may evolve insidiously over several months (Pui 2006). The presenting
symptoms and signs correlate with the leukemic cell burden and the degree of bone marrow
replacement, leading to cytopenias.
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1. Marrow failure due to infiltration
– Fatigue, pallor, – Anemia
– spontaneous bruising – Thrombocytopenia
– Infections, sepsis – Neutropenia
2.Infiltration of other organs
– liver, spleen, lymph nodes (particularly in ALL)
– Lymphadenopathy
– Hepatosplenomegaly
– Mediastinal masses (T-ALL)
– Gums
– Gum hypertrophy (monocytic subtype of acute myeloblastic leukemia)
– Bone pain, especially in children with ALL
– Skin -Leukemia cutis
– Soft tissue -Chloromas
– Testis
– Central nervous system (CNS)
– Solid organs
3. Leukostasis(only seen with WBC > 50 x 109/L)
– CNS -Strokes
– Lungs -Pulmonary infiltrates, hypoxemia
4. Constitutional symptoms
– Fevers, sweats are common
– Weight loss uncommon
5. Other
– Exposure of substances that can initiate coagulation can cause DIC
Table 1. Pathophysiology of the clinical manifestations of acute leukemias
2. Signs, symptoms and laboratory features of Acute Myeloblastic
Leukemia (AML)
Clinical manifestations of AML result either from the proliferation of leukaemic cells or from
bone marrow failure that leads to decrease in normal cells. Leukaemic cells can infiltrate tissues,
leading to hepatomegaly, splenomegaly, skin infiltrates and swollen gums. As an indirect effect
of the leukaemic proliferation leading to high cell destruction, hyperuricaemia and occasional‐
ly renal failure may occur. The haematopoiesis suppression leads to clinical features of anae‐
mia, neutropenia and thrombocytopenia. Signs and symptoms that signal the onset of AML
include pallor, fatigue, weakness, palpitations, and dyspnea on exertion. They reflect the
development of anemia; however, weakness, loss of sense of wellbeing, and fatigue on exer‐
tion may be disproportionate to the severity of anemia. (Gur et al 1999). Easy bruising, pete‐
chiae, epistaxis, gingival bleeding, conjunctival hemorrhages, and prolonged bleeding from skin
injuries reflect thrombocytopenia and are frequent early manifestations of the disease. Very
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infrequently gastrointestinal, genitourinary, bronchopulmonary, or central nervous system
bleeding can occur at the onset of the disease. Neutropenia translates into infectious manifesta‐
tions. Pustules or other minor pyogenic infections of the skin and of minor cuts or wounds are
most  common.  Major  infections  such  as  pneumonia,  pyelonephritis,  and  meningitis  are
uncommon as presenting features of the disease, in part because absolute neutrophil counts
under 500/μl (0.5 × 109/L) are uncommon until chemotherapy is begun. Anorexia and weight
loss are frequent findings. Fever is present in many patients at the time of diagnosis. Myeloid
(granulocyte) sarcoma (MS) is an extramedullary tumor that occurs in 2 to 14% of cases of AML
(John et al 2004); and is composed of immature and mature granulocytes or monocytes (Brunning
et al 2001). These neoplasms are known by a variety of names in the literature, including
granulocytic sarcoma, monocytic sarcoma, extramedullary myeloid cell tumor, myelosarco‐
ma, myeloblastoma, and chloroma (Carneiro et al. 1984, Valbuena et al 2005). Virtually any
extramedullary site can be involved by MS. Most patients with MS have a history of a myeloid
neoplasm, most often AML and less often a myelodysplastic or myeloproliferative disease
(Brunning et al 2001). Alternatively, MS can be the initial manifestation of AML that subsequent‐
ly involves blood and bone marrow (Schmitt-Graff et al 2002). Very rarely, MS can be the only
site of disease. MS is relatively more common in patients who have leukemias with prominent
monocytic differentiation, such as acute myelomonocytic or monocytic leukemia and chronic
myelomonocytic leukemia (Menasce et al 1999, Elenitoba et al 1996). MS manifesting as a
testicular mass is uncommon and only rarely has occurred as an isolated mass. The tumors are
usually localized ; they often involve bone, periostium, soft tissues, lymph nodes, or skin.
Common sites of myeloid sarcoma are orbit and paranasal sinuses. However, it should be noted
that according to the WHO classification the infiltrates of any site of the body by myeloid blasts
in AML patients are not classified as myeloid sarcoma unless they present with tumor masses
in which the tissue architecture is effaced (Pileri et al 2008).
Blasts may infiltrate organs or lymph nodes, resulting in adenopathy or hepatosplenomegaly.
Palpable splenomegaly and hepatomegaly occur in about one third of patients. Testicular
infiltration is less common in AML than ALL, with an incidence of 1 to 8 % ( Wiernik et al
2001). Meningeal involvement has been reported in 5 to 20% of children and up to 16% of adults
with AML (John et al 2004). Leukemic blast cells circulate and enter most tissues in small
numbers. Occasionally biopsy or autopsy will uncover marked aggregates or infiltrates of
leukemic cells, and less frequently collections of such cells may cause functional disturbances.
3. Signs, symptoms and laboratory features of Acute Promyelocytic
Leukemia (APL)
Acute promyelocytic leukaemia (APL) is a distinctive sub-type of acute myeloid leukaemia
that has distinct biologic and clinical features.
According to the older French-American-British (FAB) classification of AML, based solely on
morphology as determined by the degree of differentiation along different cell lines and the
extent of cell maturation (Cheson et al 1990), APL is sub-typed as AML-M3. The new World
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Health Organization (WHO) classification of AML incorporates and interrelates morphology,
cytogenetics, molecular genetics, and immunologic markers and is more universally applicable
and prognostically valid (Brunning et al 2001). APL exists as 2 types, hypergranular or typical
APL and microgranular (hypogranular) APL. APL comprises 5% to 8% of cases of AML and
occurs predominately in adults in midlife (Büchner et al. 1999). Both typical and microgranular
APL are commonly associated with DIC (Karp et al. 1987, Gollard et al 1996, Davey et al
1986, Tobelem et al 1980 ). The severe bleeding diathesis associated with APL has a specific
sensitivity to treatment with all-trans retinoic acid (ATRA), which acts as a differentiating
agent (Licht et al 1995). High complete remission rates in APL may be obtained by combining
ATRA treatment with chemotherapy (Brunning et al 2001).
4. Signs, symptoms and laboratory features of Acute Myelomonocytic
(AML-M4) and Acute Monoblastic/Monocytic Leukemia (AML-M5)
Acute myelomonocytic (M4) and monoblastic/monocytic leukemia (M5), are the morphologic
subtype of acute myelogenous leukemia that are most commonly characterized by weakness,
bleeding and a diffuse erythematous skin rash and frequently presents with extramedullary
involvement, including liver, spleen, lymph nodes, gingiva, skin, eyes, larynx, lung, bladder,
meninges and the central nervous system. Involvement of the gastrointestinal tract is rare, the
mouth, rectum and anal canal being the most affected sites (Lichtman et al 1995). By contrast,
leukemic infiltration of the stomach has been very rarely described, and when it has, it has
been mainly in children (Kasantikul et al 1989 ; Kontny et al. 1995; Domingo-Domenech et al
2000). Serum and urinary muramidase levels are often extremely high.
Neurological symptoms may occur such as, headache, nausea, vomiting, photophobia, cranial
nerve palsies, pupil edema and/ or nuchal rigidity. These symptoms may result from leuko‐
stasis, but may also reveal meningeal invasion by myeloblasts or be the presenting symptoms
of a "chloroma". These chloromas often have an orbital or periorbital localization, or may arise
around the spinal cords causing paraparesis or " Cauda equine" syndrome. CNS leukemic
infiltration occurs in 6-16% of AML (Abbott et al 2003), especially in AML-M4.
Renal insufficiency occurs seldom. It is caused by hyperuriccuria and / or hyperphosphaturia,
leading to obstructing tubular deposits and oliguria/ anuria.
5. Signs, symptoms and laboratory features of Acute Lymphoblastic
Leukemia (ALL)
The clinical presentation of ALL may range from insidious nonspecific symptoms to severe
acute life-threatening manifestations, reflecting the extent of bone marrow involvement and
degree of extramedullary spread (Pui et al 2006) (Table 2). The symptoms at onset are primarily
produced by the detrimental effects of the expanding cell population on bone marrow, and
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secondarily by the infiltration of other organs and by metabolic disturbances (Henderson et al
1990, Gur et al. 1999). In younger patients the anemia-induced fatigue may be the only
presenting feature. Dyspnea, angina, dizziness, and lethargy may reflect the degree of anemia
in older patients presenting with ALL. Approximately half of all patients may present with
fever attributable to the pyrogenic cytokines, such as IL-1, IL-6, TNF, released from the
leukemic cells, infections, or both. Arthralgia and bone pain due to bone marrow expansion
by the leukemic cells and occasionally necrosis can be observed, although less commonly in
adults compared to children. Pallor, petechiae, and ecchymosis in the skin and mucous
membranes due to thrombocytopenia, DIC, or a combination of the above may be observed.
ALL may present with either leukopenia (~20%) or moderate (50%–5–25 × 109/L) and severe
leukocytosis (10%–>100 ×109/L) with hyperleukocytosis (>100 x 109 /L ) present in approxi‐
mately 15% of the pediatric patients (Pui et al 2006). Neutropenia (less than 500 granulocytes
per mm3) is a common phenomenon and is associated with an increased risk of serious
infection. Hypereosinophilia, generally reactive, may be present at diagnosis. The majority of
patients present with platelet counts less than 100 × 109/L (75%), while 15% have platelet counts
of less than 10 × 109/L. Decreased platelet counts (median, 50x109/L) are usually present at
diagnosis and can be readily distinguished from immune thrombocytopenia, as isolated
thrombocytopenia is rare in leukemia. Severe hemorrhage is uncommon, even when platelet
counts are as low as 20x109/L, and infection and fever are absent. Coagulopathy, usually mild,
can occur in T-cell ALL and is only rarely associated with severe bleeding. More than 75% of
the patients presents with anemia, which is usually normochromic and normocytic and
associated with a normal to low reticulocyte count. Anemia or thrombocytopenia is often mild
(or even absent) in patients with T-cell ALL. Pancytopenia followed by a period of spontaneous
hematopoietic recovery may precede the diagnosis of ALL in rare cases and must be differ‐
entiated from aplastic anemia.
Bone marrow is usually infiltrated with >90% blast cells. Infiltration with less than 50% blasts
represents only 4% of cases. Though the distinction between lymphoblastic leukaemia and
lymphoma is still arbitrary, for many treatment protocols 25% bone marrow blasts is used as
threshold for defining leukaemia (Borowitz & Chan 2008). Normal trilineage haematopoiesis
is consequently decreased. The classical triad of symptoms related to bone marrow failure are
the following: (1) fatigue and increasing intolerance to physical exercise (caused by anaemia),
(2) easy bruising and bleeding from mucosal surfaces and skin (caused by thrombocytopenia
especially when platelets are <20 × 109 /L), and (3) fever with infections (40% of all cases, caused
by absolute granulocytopenia). Hyperleukocytic leukaemias with >100 x 109 /L blast cells rarely
lead to the leukostasis syndrome and catastrophic early bleeding (Porcu et al 2000 ). Also
malaise, lethargy, weight loss, fevers, and night sweats are often present but typically are not
severe. Compared to AML, patients with ALL experience more bone and joint pain. Rarely,
they may present with asymmetric arthritis, low back pain, diffuse osteopenia, or lytic bone
lesions [Gur et al 1999]. Children experience these symptoms more frequently than adults.
Young children may have difficulties in walking due to bone pain [Farhi et al 2000]. Lympha‐
denopathy, splenomegaly, and hepatomegaly are more common than in AML and affect half
of the adults with ALL. CNS involvement is also more common in ALL compared to AML.
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Patients may present with cranial neuropathies (most often involving the 6th and 7th cranial
nerves). Nausea, vomiting, headache, or papilledema may result from meningeal infiltration
and obstruction of the outflow of cerebrospinal fluid (CSF) leading to a raised intracranial
pressure. Testicular involvement, presenting as a painless, unilateral mass, is noted at
diagnosis in approximately 2% of boys. It is associated with infant or adolescent age, hyper‐
leukocytosis, splenomegaly, and mediastinal mass [Farhi et al 2000]. The diagnosis of testicular
involvement is made by wedge biopsies. Bilateral biopsies are necessary due to the high
incidence of contralateral testicular disease [Amendola et al 1985.[
6. Central nervous system involvement
The incidence of CNS involvement in patients with AML is considerably less common than
CNS involvement in both adults and children with ALL (Charles et al 2012). Early CNS
leukemia occurs in 8% of patients at the time of the first diagnosis while the percentage of
relapsing CNS leukemia is 10%. (Hardiono et al 2001).
Patients with CNS involvement may be asymptomatic or may have symptoms related to
increased intracranial pressure (headache, nausea, vomiting, irritability). All patients newly
diagnosed with ALL should have a lumbar puncture for cytologic analysis of the cerebrospinal
fluid; for AML, however, this is performed only in patients with symptoms indicative of CNS
involvement (Pavlovsky et al 1973). There is an association of central nervous system involve‐
ment and diabetes insipidus in AML with monosomy 7, abnormalities of chromosome 3 and
inversion of chromosome 16. (Glass et al 1987; Lavabre-Bertrand et al. 2001; Harb et al 2009).
Signs and symptoms Clinical and laboratory findings
Pallor, fatigue, exertional dyspnea, CHF Anemia
Fever (~50%), infection (<30% Neutropenia
Petechiae, ecchymosis, retinal hemorrhages Thrombocytopenia
Hepatomegaly, splenomegaly (~50%), lymphadenopathy
Bone pain and joint pain (5–20%)
Leukocytosis (10% of patients with
WBC > 100,000)
Leukemia cutis Leukostasis
Dyspnea, hypoxia, mental status changes, Cough, dyspnea,
chest pain
Mediastinal Mass (80% of patients with
T-cell ALL)
Headache, diplopia, cranial neuropathies, Particularly
cranial nerves VI, VIII, papilledema, nausea, vomiting
CNS involvement (<10%)
Painless testicular/scrotal enlargement Testicular involvement (<1%)
Intracranial bleeding, DIC Elevated prothrombin time (PT), partial
thromboplastin time (PTT), low fibrinogen
Tumor lysis syndrome Acute renal failure (uncommon), acidosis,
hypekalemia, hyperphosphatemia, hypocalcemia,
elevated serum LDH and, uric acid level
Table 2. Clinical features of adult acute lymphocytic leukemias
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Central nervous system hemorrhage and infection are reported to cause 80% (Lazarus et al
2006 ) of all deaths in patients with leukemia. The intracerebral hemorrhages that are often
related to intravascular leukostases and leukemic nodules, and associated with leukocyte
counts more than 100x109/L in peripheral blood (Phair et al 1964).
6.1. Leukemic parenchymal tumor
CNS may be affected as a solid tumors consisting of myeloid leukemic blasts called granulo‐
cytic sarcomas or chloromas (Recht et al 2003, Teshima et al 1990). The term chloroma results
from the greenish color of these tumors caused by the presence of myeloperoxidase. Chloromas
usually have a dural attachment although parenchymal tumors have rarely been reported.
These tumors are hypercellular and avidly enhance with either cranial magnetic resonance
imaging (MRI) or cranial computed tomography (CT). Neurologic findings are dependent
upon location. Chloromas most often occur in bone that may result in epidural spinal cord
compression, the orbit that may result in proptosis and a restrictive ophthalmopathy, or dura,
which may simulate a meningioma.
6.2. Intracranial hemorrhage
Hemorrhagic complications are common in patients with acute leukemia (approximately 20%)
and constitute the second most common cause of death in such patients (20% of all leukemic
deaths result from intracranial hemorrhage) (Kim et al 2004, Kawanami et al 2002). Intracranial
hemorrhage (ICH) is the most common hemorrhagic complication in acute promyelocytic
leukemia and is not infrequent in AML and ALL (ranging in occurrence from 2-18% of all
patients with acute leukemia). ICH may occur at the time of diagnosis (early hemorrhage) or
subsequent to diagnosis and following initial treatment (late hemorrhage) (Cortes et al 2001).
DIC, disseminated aspergillosis or mucormycosis, leukemic cell infiltration, thrombocytope‐
nia or L-asparaginase chemotherapy-related consequences, are the most common etiologies
for ICH. Both DIC (especially common in the M3 subtype of AML) and thrombocytopenia
typically result in a solitary often-massive ICH whereas disseminated fungal infection and
ICH occurring during neutropenia and is a result of hemorrhagic infarction. Leukemic cell
infiltration occurs with extreme leukocytosis (defined as >300x109 leukemic cells/L and
increase the risk of multiple intracranial hemorrhages in acute leukaemia( Bunin et al 1985).
L-asparaginase may induce hyperfibrinogenemia and result in cortical vein or sinus throm‐
bosis complicated with venous infarction. Fungal-related mycotic aneurysms may also lead to
ICH and would be a consideration in a patient with blood culture positive for fungus.
Topographically the majority of ICH is intraparenchymal with cerebral hemorrhage more
common than cerebellar. (Wolk et al 1974).
Subarachnoid hemorrhage occurs in the context of ICH, either in isolation or more frequently
as more diffuse hemorrhage secondary to DIC. Spinal subarachnoid hemorrhage may occur
in the context of DIC and acute promyelocytic leukemia and present primarily with back pain
that migrates rostrocaudally.
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Risk - factor analysis revealed that female gender, APL, leukocytosis, thrombocytopenia and
prolonged PT were the risk factors for fatal intracranial hemorrhages, while other reports have
suggested the significance of serum fibrinogen (Wide et al 1990).
6.3. Leukemic meningitis
Meningeal leukemia appears more often in patients with ALL than in those with AML (Lazarus
et al 2006). The manner in which leukemia cells enter the CNS is a subject of controversy, but
the likely source include hematogenous spread or direct spread from adjacent infiltrated bone
marrow.
Meningitis  in  leukemia  may  result  from  leptomeningeal  infiltration  of  tumor  (LM),
subarachnoid hemorrhage,  chemical  (treatment-related following intra-CSF instillation of
chemotherapy) or infection (bacterial or fungal) (Cash et al 1987, Dekker et al 1985). The
presence or absence of LM always needs to be ascertained as if  diagnosed, prognosis is
profoundly  affected.  Chemical  meningitis  (typically  due  to  intra-CSF  cytarabine  or
methotrexate  and most  often given intraventricularly)  is  temporally  related to intra-CSF
chemotherapy.  Chemical  meningitis  begins one to two days after  intra-CSF chemothera‐
py administration, It is transient typically lasting less than five days and demonstrates no
evidence of infection by CSF culture. Like other meningitis syndromes, patients complain
of headache, fever, nausea, vomiting, photophobia and meningismus. Notwithstanding an
inflammatory CSF,  chemical  meningitis  rapidly abates and is  mitigated by oral  steroids.
Infectious meningitis occurs in leukemia due to immunosuppression both as a result of the
underlying  disease  and  its  treatment.  Listeria,  Candida  and  Aspergillus  are  common
infectious etiologies  however clinical  presentation differs.  Listeria  presents  as  a  meningi‐
tise syndrome whereas Candida presents with a diffuse encephalopathy and multiple small
brain abscesses and Aspergillus  presents with progressive hemorrhagic stroke confined to
a single vascular territory (Gerson et al 1985, Winston et al 1993).
6.4. Cerebrospinal fluid in leukemic patients
The cerebrospinal fluid findings in leukemic patients must be carefully evaluated since
bacterial meningitis, abscess formation or fungal disease occur with increased frequency.
Cerebrospinal fluid pleocytosis, chemical abnormalities (elevated protein and low sugar) and
elevated pressure may be present in these potential complications of the disease or its therapy.
Appropriate cultures and stains, are often helpful in diagnosis. Abscesses can often be detected
by brain scans, electroencephalograms and arteriography.
6.4.1. Categories of CNS status at diagnosis of acute leukemia
Patients who have nontraumatic diagnostic lumbar punctures at diagnosis may be placed into
3 categories according to white blood cells (WBCs) per microliter and the presence or absence
of blasts on the cytospin: central nervous system 1 (CNS1) refers to CSF with <5 WBCs per
microliter with cytospin negative for blasts; Cxlink refers to CSF with <5 WBCs per microliter
with cytospin positive for blasts; CNS3 refers to CSF with >5 WBCs per microliter with cytospin
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positive for blasts. Children with ALL who presents with CNS disease at diagnosis (CNS3) are
at high risk for treatment failure compared with patients not meeting the criteria of the CNS
disease at diagnosis. Patients with Cxlink may be at an increased risk of CNS relapse, although
this may not apply to all treatment regimens and can be overcome by more intensive intrathecal
treatment (Burger et al 2003).
7. Testicular involvement
Involvement of the testis - one of the most common sites of relapse in acute lymphoblastic
leukemia usually presents with painless enlargement of one or both testis. Testicular involve‐
ment occurs in 10% to 23% of boys during the course of the disease at a median time of 13
months from diagnosis. Occult testicular involvement is recognized in 10% to 33% of boys
undergoing bilateral wedge biopsies performed during the first 3 years of treatment or at any
time after cessation of the therapy (Lanzkowsky et al. 1985). In a study in which biopsies were
done in boys with newly diagnosed ALL, microscopic testicular involvement was reported to
be 21% (Neimeyer et al 1993). Testicular involvement of the endothelial side of the interstitium
of one or both testis, leads to increased testicular size and firmness [Kay et al 1983 ]. Hydrocele
resulting from lymphatic obstruction may also present with painless scrotal enlargement and
is readily identified by ultrasonography. Overt testicular involvement may occur in any form
of acute lymphoblastic leukemia, most commonly in common C-ALL, but also in T-ALL and
B-ALL. Rarely it is present when ALL is first diagnosed, but most often it is a late complication
and, as with meningeal leukemia, the higher the initial blood blast count is, the earlier the
discovery of testicular disease is likely ( Nesbit et al 1980).
8. Superior vena cava syndrome
Superior vena cava syndrome comprises the signs and symptoms associated with compression
or obstruction to the superior vena cava. Patients with ALL (particularly T-ALL), may present
with symptoms of cough, dyspnea, stridor, or dysphagia from tracheal and esophageal
compression by a mediastinal mass (15% of patients). Compression of the great vessels by a
bulky mediastinal mass also may lead to the life threatening superior vena cava syndrome
(Marwaha et al 2011). A child with leukemia may experience anxiety, confusion, drowsiness
and sometimes unconsciousness (Salsali et al 1969). There is facial edema, plethora, cyanotic
faces. Venous engorgement of neck, chest and arm with collateral vessel and some sign of
pleural effusion and pericardial effusion may be present (Rice et al 2006).
9. Skin involvement
Various cutaneous lesions can be observed in patients with acute leukemias. These include
specific cutaneous lesions resulting from infiltration of the skin by the leukemic cells, charac‐
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teristic diseases such as pyoderma gangrenosum and Sweet syndrome, cutaneous signs of
infection or hemorrhage resulting from the bone marrow dysfunction induced by the malig‐
nant process or chemotherapy.
Skin involvement may be of three types: nonspecific lesions, leukemia cutis, or granulocyt‐
ic  sarcoma of  skin  and subcutis.  Nonspecific  lesions  include  macules,  papules,  vesicles,
pyoderma gangrenosum, or vasculitis (Bourantas et al. 1994, Nambiar Veettil et al 2009),
neutrophilic dermatitis (Sweet's syndrome) (Cho K-H et al 1997, Philip R Cohen 2007), cutis
vertices  gyrata,  or  erythema multiforme  or  nodosum (Byrd  et  al  1995).  Leukemia  cutis
lesions  usually  appear  at  the  time  of  diagnosis  of  systemic  disease  or  thereafter,  but
occasionally can occur before peripheral  blood or bone marrow involvement (aleukemic
leukemia cutis). (Christos Tziotzios et al 2011, Márcia Ferreira et al 2006). T-cell ALL may
show epidermotropism and monocytic leukemia often involves the entire dermis and the
superficial panniculus (Yalcin et al 2004).
10. The gastrointestinal tract
Gastrointestinal (GI) manifestations of leukemia occur in up to 25% of patients at autopsy,
generally during relapse. Its presence varies with the type of leukemia and has been decreasing
over time due to improved chemotherapy. Gross leukemic lesions are most common in the
stomach, ileum, and proximal colon. Leukemia in the esophagus and stomach includes
hemorrhagic lesions from petechiae to ulcers, leukemic infiltrates, pseudomembranous
esophagitis, and fungal esophagitis. (Dewar et al. 1981) The mouth, colon, and anal canal are
sites of involvement that most commonly lead to symptoms. Oral manifestations may bring
the patient to the dentist; gingival or periodontal infiltration and dental abscesses may lead to
an extraction followed by prolonged bleeding or an infected tooth socket. (Dean et al. 2003).
The gingival hyperplasia is most commonly seen with the AML subtypes acute monocytic
leukemia M5 (67%), acute myelomonocytic leukemia M4 (18.5%) and acute myelocytic
leukemia M1-M2 (3.7%) (Cooper et al 2000). Enterocolitis, a necrotizing inflammatory lesion
involving the terminal ileum, cecum, and ascending colon, can be a presenting syndrome or
can occur during treatment. Fever, abdominal pain, bloody diarrhea, or ileus may be present
and occasionally mimic appendicitis. Intestinal perforation, an inflammatory mass, and
associated infection with enteric gram-negative bacilli or clostridial species are often associated
with a fatal outcome. Isolated involvement of the gastrointestinal tract is rare.(Tim et al 1984)..
Neutropenic enterocolitis (NE), which is a fulminant necrotizing process is a well-recognized
complication of neutropenia in patients dying from hematologic malignancies especially acute
leukemia as indicated by various autopsy series ( Steinberg et al 1973). Proctitis, especially
common in the monocytic variant of AML, can be a presenting sign or a vexing problem during
periods of severe granulocytopenia and diarrhea.(Christos Tziotzios et al. 2011)
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11. Respiratory tract involvement
Infectious and noninfectious pulmonary complications represent a critical problem for patients
with leukemia, which itself can be the direct cause of pulmonary leukostasis, pulmonary
leukemic infiltration (PLI), and leukemic cell lysis pneumopathy. These disorders are usually
more frequent in patients with hyperleukocytic leukemia. Pulmonary leukostasis is charac‐
terized by occlusion of the pulmonary capillaries and arterioles by leukemic cells. Leukemic
infiltration may lead to laryngeal obstruction, parenchymal infiltrates, alveolar septal infiltra‐
tion, or pleural seeding. Each of these events can result in severe symptoms and radiologic
findings (Potenza et al 2003, Wu et al 2008).
Pulmonary disease in leukaemia is frequent and often lethal. Lung involvement in leukaemia
is primarily due to (a) leukostasis of vessels and (b) true leukaemic infiltration of interstitium
and alveoli. (Majhail et al 2004, Porcu et al 2000) Clinically, leukostasis in leukaemia should
be suspected in patients with unexplained fever and cardiopulmonary or cerebral dysfunction.
Pulmonary leukostasis was found in about40% of autopsy series. (Mark et al 1987). Maile et
al 1983 noted parenchymal opacities on 90% of chest radiographs obtained shortly before death
in adult patients with leukaemia. These radiologic opacities on autopsy were attributed to
infections, haemorrhages, leukaemic infiltrations and edema. In addition, drug induced
pulmonary infiltrates and leukoagglutinin transfusion reactions were also reported (Mark et
al 1987). In spite of the above data, pulmonary leukostasis in leukaemia has been mentioned
only incidentally as a cause of abnormalities on chest radiography.
12. Cardiac complications
Cardiac complications of the patients with acute leukemia are common. Most of the cardiac
complications may be due to chemotherapeutics such as antracyclins, besides anemia,
infections, or direct leukemic infiltrations of the heart. Symptomatic pericardial infiltrates,
transmural ventricular infiltrates with hemorrhage, and endocardial foci with associated
intracavitary thrombi can, on occasion, cause heart failure, arrhythmia, and death. Infiltration
of the conducting system or valve leaflets or myocardial infarction may occur. (Ashutosh et al
2002, Fernando et al 2004). Cardiac and other tissue damage as a consequence of release of
eosinophil granule contents can occur in patients with leukemia, associated with eosinophilia
(Kocharian et al 2006). Cardiac damage is a major determinant of the overall prognosis.
13. Urogenital involvement
The urogenital organs can also be affected. The kidneys are infiltrated with leukemic cells in
a high proportion of cases, but functional abnormalities are rare. Hemorrhages in the pelvis
or the collecting system are frequent, however, cases of vulvar, bladder neck, prostatic, or
testicular involvement have been described.. (Quien et al 1996).




Musculoskeletal manifestations are the presenting complaint in up to 20% of patients with
pediatric leukemia,(Andreas et al 2007). The main clinical osteoarticular manifestations in early
leukemia include limb pain, nighttime pain, arthralgia, and arthritis. Skeletal manifestations
of acute leukaemia (bone or back pain, arthritis or radiographical abnormalities of skeleton)
are well described in children (Barbosa et al 2002). Arthritis can occur at any time during the
course of acute leukaemia. It may lead to delay in diagnosis and therapy and any delay in
therapy is associated with poor prognosis (Sandeep et al 2006). The most common clinical
presentation of leukaemic arthritis is additive or migratory asymmetrical oligoarticular large
joint arthritis and in some cases juvenile idiopathic arthritis. (Evans et al. 1994, Mirian et al.
2011). The joints most commonly involved are the knee, followed by the ankle, wrist, elbow,
shoulder and hip. Onset of arthritis may be sudden or insidious, and parallel the course of
acute leukaemia (Sandeep et al. 2006).
Arthritis as the first manifestation of acute leukaemia is however extremely uncommon in
adults.
15. Hyperleukocytosis and leukostasis
Leukostasis is a syndrome, caused by clumping of leukocytes in the vasculature of the lungs
and brain, often resulting in hypoxia, dyspnea, confusion, and coma, and may be fatal.
Leukapheresis is indicated in the initial management of leukostasis in patients with hyper‐
leukocytosis in acute leukemias, particularly myeloid leukemias, or in patients who are at high
risk of developing such a complication.
Adult T-cell leukemia/lymphoma is a distinct form of ALL that presents with progressive
lymphadenopathy, hepatosplenomegaly, and hypercalcemia. It involves the skin, lungs, bone
marrow, intestinal tract, and CNS. This disease is associated with HTLV-1 and is endemic in
the Caribbean, southeastern United States, Africa, and Japan. Circulating tumor cells have a
characteristic “cloverleaf”-shaped nucleus.
The risk factors for leukostasis are acute the leukaemia itself, younger age (most common in
infants), certain types of leukaemia like acute promyelocytic (microgranular variants), acute
myelomonocytic, acute monocytic leukaemia and T cell type of ALL. Cytogenetic abnormali‐
ties – 11q23 translocations and presence of Philadelphia chromosome are also associated with
leukostasis (Porcu et al 2000). The pathogenesis of leukostasis is determined by: - 1) sluggish
flow with stasis, 2) aggregation of leukaemic cells, 3) formation of microthrombi, 4) release of
toxic granules, 5) endothelial damage, 6) oxygen consumption by leukocytes, 7) tissue inva‐
sion (Litchman et al 1987). Leukostasis is usually associated with counts of >100 x 109 but acute
monocytic leukaemia may present with leukostasis with counts of 50 x 109/L. 5-13% of patients
of AML and 10-30% of patients of ALL will manifest with hyperleukocytosis. Earlier leukosta‐
sis was thought to be due to the presence of critical leukocrit (fractional leukocyte volume) and
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increased viscosity. Although hyperleukocytosis is also common presenting feature in pa‐
tients with ALL, particularly with T-cell phenotype, 11q23, and t(9;22) chromosomal rearrange‐
ments, symptomatic leukostasis is exceedingly rare [Porcu et al 2000]. While WBC count is a
major factor contributing to microvessel occlusion seen with leukostasis, other features, such as
activation of adhesion cell surface markers and mechanical properties of the leukemic blasts, are
likely to be important. For example, the stiffness of myeloid blasts, as measured by atomic force
microscopy, is 18 times that of lymphoid blasts [Rosenbluth et al 2006]. This difference in
deformability of the cells may at least partially explain the increased frequency of leukostasis in
AML compared to than in ALL. Presence of symptoms suggestive of leukostasis, such as
headache, blurred vision, dyspnea, hypoxia, constitute a medical emergency and efforts should
be made to lower the WBC rapidly. However, the role of leukapheresis to reduce tumor burden
in patients with ALL and leukocytosis remains controversial.
16. Metabolic complications
Hyperuricemia and hyperphosphatemia with secondary hypocalcemia are frequently en‐
countered at diagnosis, even before chemotherapy is initiated, especially in patients with B-
cell or T-cell ALL with high leukemic cell burden. Severe metabolic abnormalities may
accompany the initial diagnosis of ALL and AML (Haralampos et al 1999). Patients with high
leukemic burden are at risk of developing acute tumor lysis syndrome (ATLS). Such metabolic
changes may lead to the development of oliguric renal failure due to the tubular precipitation
of urate and calcium phosphate crystals, fatal cardiac arrhythmias, hypocalcemic tetany, and
seizures ( Jeha 2001).
17. Lactic acidosis
Lactic acidosis (LA), as the presenting manifestation of acute leukemia, is rare, but potentially
fatal complication of acute leukemia (Grossman et al 1983), characterized by low arterial pH
due to the accumulation of blood lactate. It has been suggested that LA occurring in the setting
of hematological malignancy is associated with an extremely poor prognosis [Sillos et al
2001]. Lactate, the end product of anaerobic glycolysis, is metabolized to glucose by the liver
and kidneys. Because leukemic cells have a high rate of glycolysis even in the presence of
oxygen and produce a large quantity of lactate, LA may result from an imbalance between
lactate production and hepatic lactate utilization [Sillos et al 2001]. Several factors may
contribute to the high rate of glycolysis. Overexpression or aberrant expression of glycolytic
enzymes, such as hexokinase, the first rate-limiting enzyme in the glycolytic pathway
[Mazurek et al 1997] allows leukemic blasts to proliferate rapidly and survive for prolonged
periods [Mathupala et al 1997]. Although insulin normally regulates the expression of this
enzyme, insulin-like growth factors (IGFs) that are overexpressed by malignant leukemic cells,
can mimic insulin activity [Werner 1996,]. LA is frequently associated with acute tumor lysis
syndrome (ATLS) and its extent is correlated with the severity of ATLS.
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Typically, the patient with lactic acidosis presents with weakness, tachycardia, nausea, mental
status changes, hyperventilation, and hypotension, which may progress to frank shock as
acidosis worsens. Laboratory studies show a decreased blood pH (<7.37), a widened anion gap
(>18), and a low serum bicarbonates.
HCT-CI weighted scores Definitions of comorbidities included in
the new HCT-CI
Comorbidity
1 Atrial fibrillation or flutter, sick sinus
syndrome, or ventricular arrhythmias
Arrhythmia
1 Coronary artery disease - one or more
vessel-coronary artery stenosis requiring
medical treatment, stent, or bypass graft,
congestive heart failure, myocardial
infarction, or EF ≤ 50%
Cardiac
1 Crohn disease or ulcerative colitis Inflammatory bowel disease
1 Requiring treatment with insulin or oral
hypoglycemics but not diet alone
Diabetes
1 Transient ischemic attack or
cerebrovascular accident
Cerebrovascular disease
1 Depression or anxiety requiring psychiatric
consult or treatment
Psychiatric disturbance
1 Chronic hepatitis, bilirubin > ULN to 1.5 ×
ULN, or AST/ALT > ULN to 2.5 × ULN
Hepatic, mild
1 Patients with a body mass index > 35
kg/m2
Obesity
1 Requiring continuation of antimicrobial
treatment after day 0
Infection
2 SLE, RA, polymyositis, mixed CTD, or
polymyalgia rheumatica
Rheumatologic
2 Requiring treatment Peptic ulcer
2 Serum creatinine > 2 mg/dL, on dialysis, or
prior renal transplantation
Moderate/severe rena
2 DLco and/or FEV1 66%-80% or dyspnea
on slight activity
Moderate pulmonary
3 Treated at any time point in the patient's
past history, excluding nonmelanoma skin
cancer
Prior solid tumo
3 Except mitral valve prolapse Heart valve disease
3 DLco and/or FEV1 ≤ 65% or dyspnea at
rest or requiring oxygen
Severe pulmonary
3 Liver cirrhosis, bilirubin > 1.5 × ULN, or
AST/ALT > 2.5 × ULN
Moderate/severe hepatic
Table 3. Definitions of comorbidities and HCT-CI scores included in the HCT-CI
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18. Comorbidity
Many factors have been studied to predict outcome and allocate treatment in acute leukemia.
The best established prognostic factors are karyotype and age. However, comorbidity may
play an important role in the outcome.
A comprehensive assessment including performance status, evaluation of comorbidities and
abilities to perform activities of daily living, geriatric depression scale in elderly patients has
been proven to be useful in detecting treatment-related changes in older cancer patients and
has been recommended to be incorporated into clinical outcome analysis. An index developed
specifically for patients with hematologic malignancies has been developed: the Hematopoiet‐
ic Cell Transplantation-Specific Comorbidity Index (HCT-CI) presented in Table 3 (Sorror ML
et al 2005). This index captures comorbidities that predict non-relapse mortality in patients
considered for allogeneic transplant and also proved to be a helpful tool for defining comorbid
conditions in elderly untreated AML patients. (Novotny J et al 2009; Sorror ML et al 2007).
Modifications such as modified EBMT risk score have been developed and evaluated for ALL
patients (Terwey T et al, 2010).
Comorbidity scoring is currently still under the investigation in many cooperative groups. It
is important to bear in mind that when translating the results from clinical trials into treatment
decision-making for the individual patient, many patients with e.g. „unacceptable“ renal,
cardial or hepatic abnormalities are generally not included into clinical trials. By such approach
at least 20-30% of younger patients and more than 50% of elderly patients with AML are
excluded and have not been reported in any results. Because of that it would be important to
propose comorbidity score for all leukemia patients and to evaluate how many of the patients
are able to receive standard therapy and stem cell transplantation, how many of them are
candidate for low-intensity treatment and supportive care.
While acute leukemia patients depend on the expert recommendations from their physicians,
knowledge of clinical presentation and patient's related prognostic factors can help to improve
treatment decision and to identify patients who would benefit most from either intensive or
low-intensive treatment or even best supportive care alone.
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